<DOC>
	<DOC>NCT00233610</DOC>
	<brief_summary>The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.</brief_summary>
	<brief_title>Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gynecomastia</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically confirmed prostate cancer Locally advanced prostate cancer patients suitable for Casodex 150 mg monotherapy Age &gt; 75 yrs No metastatic disease (M1). No presence of gynaecomastia and/or mastalgia at screening No therapy with medications able to provoke gynaecomastia and/or mastalgia within 6 months of trial entry.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Casodex monotherapy</keyword>
</DOC>